# EDGAR Filing Document

**Accession Number:** 0001757499
**File Stem:** 0001493152-25-014097
**Filing Date:** 2025-9
**Character Count:** 5206
**Document Hash:** 7e3c3970a7cc9b5ea50f994b1ffeb2f8
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0001493152-25-014097.hdr.sgml**: 20250918

**ACCESSION NUMBER**: 0001493152-25-014097

**CONFORMED SUBMISSION TYPE**: 8-K

**PUBLIC DOCUMENT COUNT**: 12

**CONFORMED PERIOD OF REPORT**: 20250912

**ITEM INFORMATION**: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers

**FILED AS OF DATE**: 20250918

**DATE AS OF CHANGE**: 20250918

**FILER**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** Shuttle Pharmaceuticals Holdings, Inc.
- **CENTRAL INDEX KEY:** 0001757499
- **STANDARD INDUSTRIAL CLASSIFICATION:** PHARMACEUTICAL PREPARATIONS [2834]
- **ORGANIZATION NAME:** 03 Life Sciences
- **EIN:** 000000000
- **STATE OF INCORPORATION:** DE
- **FISCAL YEAR END:** 1231

**FILING VALUES:**
- **FORM TYPE:** 8-K
- **SEC ACT:** 1934 Act
- **SEC FILE NUMBER:** 001-41488
- **FILM NUMBER:** 251324341

**BUSINESS ADDRESS:**
- **STREET 1:** 401 PROFESSIONAL DRIVE
- **STREET 2:** SUITE 260
- **CITY:** GAITHERSBURG
- **STATE:** MD
- **ZIP:** 20879
- **BUSINESS PHONE:** (240) 403-4212

**MAIL ADDRESS:**
- **STREET 1:** 401 PROFESSIONAL DRIVE
- **STREET 2:** SUITE 260
- **CITY:** GAITHERSBURG
- **STATE:** MD
- **ZIP:** 20879

?xml version='1.0' encoding='ASCII'?

**UNITED STATES**

**SECURITIES AND EXCHANGE COMMISSION**

**Washington, D.C. 20549**

**FORM 8-K**

**CURRENT REPORT**

**Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934**

Date of Report (Date of earliest event reported): **September 12, 2025**

**SHUTTLE PHARMACEUTICALS HOLDINGS, INC.**

(Exact name of registrant as specified in its charter)

<u>Delaware</u> <u>001-41488</u> <u>82-5089826</u> <br> (State or other jurisdiction of incorporation) (Commission File Number) (IRS Employer Identification No.)

401 Professional Drive, Suite 260

Gaithersburg, MD 20879

(Address of principal executive offices) (Zip Code)

(240) 430-4212

(Registrant's telephone number, including area code)

N/A

(Former name or former address, if changed since last report.)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

---

| | | |
|:---|:---|:---|
| Title of each class | Trading Symbol(s) | Name of each exchange on which registered |
| Common Stock $0.00001 per share | SHPH | The Nasdaq Stock Market LLC |

---

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company ☒

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

**Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.**

On September 12, 2025, Sachin Pathigoda and Angel Liriano were appointed as directors of Shuttle Pharmaceuticals Holdings, Inc. (the "Company"). On September 15, 2025, Mr. Pathigoda was also appointed as the Chairman of the Nominating and Corporate Governance Committee and Mr. Liriano was appointed as the Chairman of the Compensation Committee. In addition, Mr. Pathigoda was appointed as a member of the Audit Committee and Mr. Liriano was appointed as a member of the Nominating and Corporate Governance Committee.

In addition, George Scorsis, a director of the Company, was appointed as Chairman of the Audit Committee.

There are no family relationships between Mr. Pathigoda or Mr. Liriano and any of the Company's directors or executive officers. Neither Mr. Pathigoda nor Mr. Liriano have any direct or indirect material interest in any transaction required to be disclosed pursuant to Item 404(a) of Regulation S-K. There were no arrangements or understandings by which Mr. Pathigoda and Mr. Liriano were appointed as directors of the Company..

**SIGNATURES**

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

---

| | | |
|:---|:---|:---|
|  | SHUTTLE PHARMACEUTICALS HOLDINGS, INC. | SHUTTLE PHARMACEUTICALS HOLDINGS, INC. |
| Dated: September 18, 2025 |  |  |
|  | By: | */s/ Christopher Cooper&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;* |
|  | Name: | Christopher Cooper |
|  | Title: | Interim Chief Executive Officer |

---